Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from SSY Group ( (HK:2005) ).
SSY Group Limited has announced that its Ambroxol Hydrochloride has received approval from China’s National Medical Products Administration to be marketed as a bulk drug. This development signifies a significant advancement in the company’s product offerings, potentially enhancing its market position in the respiratory treatment sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company’s primary products include drugs and treatments for various health conditions, with a market focus on respiratory diseases.
YTD Price Performance: -7.62%
Average Trading Volume: 14,295,131
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.27B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.